Clinical trial · Interventional
Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma
SIOP Study of Combined Modality Treatment in Childhood Ependymoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying combination chemotherapy and radiation therapy to see how well they work in treating children with localized ependymoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | Central Nervous System Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy | Procedure | — | UNRESOLVED |
| conventional surgery | Procedure | — | UNRESOLVED |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
| vincristine sulfate | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Event-free survival
- measure
- Overall survival
- measure
- Surgical operability
- measure
- Response rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 20 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven nonmetastatic intracranial ependymoma * Cellular * Papillary * Clear cell * Mixed cell * Anaplastic * No myxopapillary ependymoma, subependymoma, or ependymoblastoma PATIENT CHARACTERISTICS: Age: * 3 to 20 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * No hematologic disease that would preclude study participation Hepatic: * Not specified Renal: * No renal disease that would preclude study participation Other: * No concurrent unrelated disease that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy Endocrine therapy: * Prior steroids allowed Radiotherapy: * No prior radiotherapy Surgery: * Not specified
References
Publications (0)
Data not yet available